Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

Research and Development (R&D) expenses: R&D expenses were $24.8 million for the fourth quarter of 2024, compared to $42.0 million for the fourth quarter of 2023. R&D expenses were $117.0 million for ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

Phase 2 open-label study of paltusotine in carcinoid syndrome reported positive results. In March 2024, Crinetics reported ...

It is rated on a 2026 PE ratio of 10 even though the integration of bolt-on acquisitions will help drive future growth ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...